1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. Massachusetts >
  6. Ipsen Acquires Albireo

M&A Deal Summary

Ipsen Acquires Albireo

On January 9, 2023, Ipsen acquired life science company Albireo for 952M USD

Acquisition Highlights
  • This is Ipsen’s 11th transaction in the Life Science sector.
  • This is Ipsen’s largest (disclosed) transaction.
  • This is Ipsen’s 5th transaction in the United States.
  • This is Ipsen’s 3rd transaction in Massachusetts.

M&A Deal Summary
Date 2023-01-09
Target Albireo
Sector Life Science
Buyer(s) Ipsen
Deal Type Add-on Acquisition
Deal Value 952M USD
Advisor(s) Centerview Partners
Chestnut Partners (Financial)
Paul, Weiss, Rifkind, Wharton & Garrison
Mintz Levin Cohn Ferris Glovsky and Popeo (Legal)

Target

Albireo

Boston, Massachusetts, United States
Albireo is a rare disease company focused on the development of novel bile acid modulators to treat pediatric and adult liver diseases. Albireo’s lead product, Bylvay, was approved by the U.S. FDA as the first drug for the treatment of pruritus in all types of progressive familial intrahepatic cholestasis (PFIC), and in Europe for the treatment of PFIC. Bylvay is also being developed to treat other rare pediatric cholestatic liver diseases with a completed Phase III trial in ALGS, an ongoing Phase III study in biliary atresia, as well as Open-label Extension (OLE) studies for PFIC and ALGS. The company has also completed a Phase I clinical trial for A3907 to advance development in adult cholestatic liver disease, with IND-enabling studies progressing with A2342 for viral and cholestatic liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden.

Search 215,058 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Ipsen

Boulogne-Billancourt, France
Category Company
Founded 1929
Sector Life Science
Employees5,358
Revenue 3.6B EUR (2024)
DESCRIPTION

Ipsen is a research and development pharmaceutical company. It manufactures specialty pharmaceuticals and has a worldwide sales presence. Ipsen focuses on products in the gastro-enterology, neurology and cardiovascular therapeutic areas and has also developed specific expertise in some biotech niches such as endocrinology, oncology, neurology and hematology. Ipsen was founded in 1929 and is based in Boulogne-Billancourt, France.

DEAL STATS #
Overall 11 of 12
Sector: Life Science M&A 11 of 12
Type: Add-on Acquisition M&A Deals 8 of 9
State: Massachusetts M&A 3 of 3
Country: United States M&A 5 of 5
Year: 2023 M&A 1 of 1
Size (of disclosed) 1 of 5
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-06-27 Epizyme

Cambridge, Massachusetts, United States

Epizyme is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme was founded in 2007 and is based in Cambridge, Massachusetts.

Buy $247M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2025-10-22 Imcheck Therapeutics

Marseilles, France

ImCheck Therapeutics is a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel superfamily of immunomodulators. Its clinical-stage program, ICT01, has been advancing to late-stage trials, demonstrating a unique mechanism of action that modulates both innate and adaptive immunity. These “first-in-class” activating antibodies may deliver superior clinical outcomes compared to first-generation immunotherapy approaches, in particular in rational combinations with immune checkpoint inhibitors and immunomodulatory anti-cancer drugs. Imcheck Therapeutics was founded in 2015 and is based in Marseilles, France.

Buy -
Mergr

Solution for

Product

Company

Legal